Drug-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of Nobori (Biolimus A9 Eluting Stent) in primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Accordingly, the investigators will compare the outcomes of primary PCI for AMI between patients receiving Nobori versus uncoated stents.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,537
implantation of Biolimus A9 eluting stents
implantation of any uncoated bare metal stents currently available in Japan
major adverse cardiac and cerebrovascular events (MACE)
MACE includes all-cause death, myocardial infarction, cerebrovascular events, and target lesion revascularization
Time frame: 1 year
major adverse cardiac and cerebrovascular events (MACE)
MACE includes all-cause death, myocardial infarction, cerebrovascular events, and target lesion revascularization
Time frame: 1 week
stent thrombosis
Time frame: 1 week and 1 year
target lesion revascularization
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Shonan Atsugi Hospital
Atsugi, Kanagawa, Japan
Shonan Kamakura General Hospital
Kamakura, Kanagawa, Japan
Tokyo nishi tokusyukai hospital
Akishima, Japan
Shonan Atsugi hospital
Atsugi, Japan
Tokai University Hachioji Hospital
Hachiōji, Japan
Hakodate Municipal Hospital
Hakodate, Japan
Hiratsuka kyosai hospital
Hiratsuka, Japan
Tokai University Hospital
Isehara, Japan
Ishikawa Prefectural Central Hospital
Ishikawa, Japan
Kanazawa Cardiovascular Hospital
Kanazawa, Japan
...and 40 more locations